BTIG Research Reaffirms Buy Rating for Boston Scientific (NYSE:BSX)

Key Points

• BTIG Research has reiterated a buy rating for Boston Scientific (NYSE:BSX) and set a price target of $127.00, indicating a potential upside of 31.05% from its previous close.
• Boston Scientific recently reported quarterly earnings of $0.75 EPS, surpassing market expectations, with revenue of $5.06 billion, reflecting a year-over-year growth of 22.8%.
• Institutional investors own about 89.07% of Boston Scientific's stock and have been active in adjusting their positions, with several firms reporting increased holdings in recent months.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They currently have a $127.00 price objective on the medical equipment provider's stock. BTIG Research's price objective would suggest a potential upside of 31.05% from the company's previous close.

A number of other research analysts have also commented on BSX. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $118.17.

Boston Scientific Stock Down 0.9%

Boston Scientific stock opened at $96.91 on Tuesday. Boston Scientific has a 1-year low of $80.64 and a 1-year high of $109.50. The firm has a market capitalization of $143.60 billion, a price-to-earnings ratio of 57.69, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a 50 day simple moving average of $104.25 and a 200 day simple moving average of $102.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,802,597.06. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. HM Payson & Co. boosted its position in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after acquiring an additional 98 shares in the last quarter. Riverwater Partners LLC boosted its position in Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after acquiring an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its position in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock valued at $291,000 after acquiring an additional 99 shares in the last quarter. IVC Wealth Advisors LLC boosted its position in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock valued at $236,000 after acquiring an additional 102 shares in the last quarter. Finally, Park Square Financial Group LLC boosted its position in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.